# EDGAR Filing Document

**Accession Number:** 0001627223
**File Stem:** 0001627223-26-000010
**Filing Date:** 2026-5
**Character Count:** 60033
**Document Hash:** ef4d379478320cb105c38f1a3898d0f5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001627223-26-000010.hdr.sgml**: 20260505

**ACCESSION NUMBER**: 0001627223-26-000010

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260505

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260505

**DATE AS OF CHANGE**: 20260505

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Chemours Co
- **CENTRAL INDEX KEY:** 0001627223
- **STANDARD INDUSTRIAL CLASSIFICATION:** CHEMICALS & ALLIED PRODUCTS [2800]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 464845564
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36794
- **FILM NUMBER:** 26944393

**BUSINESS ADDRESS:**
- **STREET 1:** 1007 MARKET STREET
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801
- **BUSINESS PHONE:** 302 773 1000

**MAIL ADDRESS:**
- **STREET 1:** 1007 MARKET STREET
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Chemours Company, LLC
- **DATE OF NAME CHANGE:** 20141205

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM** 8-K

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

May 5, 2026

Date of Report (Date of Earliest Event Reported)

![img13577996_0.jpg](img13577996_0.jpg)

The Chemours Company

(Exact Name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| Delaware | 001-36794 | 46-4845564 |
| (State or Other Jurisdiction | (Commission | (I.R.S. Employer |
| Of Incorporation) | File Number) | Identification No.) |

---

1007 Market Street

Wilmington**,** Delaware 19801

(Address of principal executive offices)

Registrant's telephone number, including area code: (302) 773-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of Each Class** | **Name of Exchange on Which Registered** |
| Common Stock ($0.01 par value)<br> CC | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.**

On May 5, 2026, The Chemours Company (the "Company") issued a press release regarding its first quarter 2026 financial results. A copy of the press release is furnished hereto as Exhibit 99.1. The Company will post to its investor relations website, investors.chemours.com, an investor presentation by 8:00 a.m. Eastern Daylight Time on Wednesday, May 6, 2026, for its conference call scheduled for that time.

The information furnished with this report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it will not be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1 [<u>Press release dated May 5, 2026.</u>](cc-ex99_1.htm)

104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| THE CHEMOURS COMPANY | THE CHEMOURS COMPANY |
| By: | /s/ Shane Hostetter |
|  | Shane Hostetter |
|  | Senior Vice President, Chief Financial Officer |
| Date: | May 5, 2026 |

---

------

## Exhibit 99.1

**EXHIBIT 99.1**

![img15408389_0.jpg](img15408389_0.jpg)

**The Chemours Company Reports First Quarter Results**

**Wilmington, Del.,** May 5, 2026 – The Chemours Company ("Chemours" or "the Company") (NYSE: CC), a global chemistry company with leading market positions in Thermal & Specialized Solutions ("TSS"), Titanium Technologies ("TT"), and Advanced Performance Materials ("APM"), today announced its financial results for the first quarter 2026.

**Key First Quarter 2026 Results & Recent Highlights**<sup>1</sup>

• Net Sales of $1.4 billion, slightly up compared to the corresponding prior-year quarter, with TSS reporting record first quarter results, with continued double-digit year-over-year sales growth in Opteon™ Refrigerants

• Net Loss attributable to Chemours of $29 million, or $0.19 per diluted share, compared with Net Loss attributable to Chemours of $5 million, or $0.03 per diluted share, in the corresponding prior-year quarter

• Adjusted Net Income<sup>2</sup> of $8 million, or $0.05 per diluted share, compared to Adjusted Net Income of $19 million, or $0.13 per diluted share, in the corresponding prior-year quarter

• Adjusted EBITDA<sup>2,3</sup> of $169 million compared to $166 million in the corresponding prior-year quarter

• Announced a global TiO2 price increase effective April 1, 2026, as a continuation of our December price actions; achieved a sequential TiO2 price increase of 3% in Net Sales

• Received ~$287 million initial net proceeds from the sale of the Kuan Yin site, positioning the Company to paydown €140 million of outstanding debt

*"Chemours exceeded overall expectations in the first quarter, achieving strong outcomes from both our TSS and TT businesses, paired with the more recent receipt of cash through the completion of a substantial portion of our Kuan Yin property sales enabling us to reduce our debt," stated Denise Dignam, Chemours President and CEO. "These achievements demonstrate our dedication to our Pathway to Thrive strategy and highlight the importance we place on effective execution. While the wider economic landscape remains uncertain, Chemours continues to drive full-year growth while remaining steadfast in prioritizing flexible commercial and operational strategies to ensure Chemours is able to capitalize on opportunities in our key markets."* 

**Total Chemours**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Q1 2026** | &nbsp;&nbsp;**Q1 2025** | &nbsp;&nbsp;**Y-o-Y % ∆** | &nbsp;&nbsp;**Q4 2025** | &nbsp;&nbsp;**Q-o-Q % ∆** |
| &nbsp;&nbsp;Net Sales *(millions)* | &nbsp;&nbsp;$1381 | &nbsp;&nbsp;$1368 | &nbsp;&nbsp;1% | &nbsp;&nbsp;$1329 | &nbsp;&nbsp;4% |
| &nbsp;&nbsp;Net Loss (*millions)* | &nbsp;&nbsp;($29) | &nbsp;&nbsp;($5) | &nbsp;&nbsp;(480%) | &nbsp;&nbsp;($47) | &nbsp;&nbsp;38% |
| &nbsp;&nbsp;Loss Per Share<sup>4</sup> | &nbsp;&nbsp;($0.19) | &nbsp;&nbsp;($0.03) | &nbsp;&nbsp;(533%) | &nbsp;&nbsp;($0.31) | &nbsp;&nbsp;39% |
| &nbsp;&nbsp;Adjusted Net Income | &nbsp;&nbsp;$8 | &nbsp;&nbsp;$19 | &nbsp;&nbsp;(58%) | &nbsp;&nbsp;$7 | &nbsp;&nbsp;14% |
| &nbsp;&nbsp;Adjusted EPS | &nbsp;&nbsp;$0.05 | &nbsp;&nbsp;$0.13 | &nbsp;&nbsp;(62%) | &nbsp;&nbsp;$0.05 | &nbsp;&nbsp;0% |
| &nbsp;&nbsp;Adjusted EBITDA *(millions)* | &nbsp;&nbsp;$169 | &nbsp;&nbsp;$166 | &nbsp;&nbsp;2% | &nbsp;&nbsp;$128 | &nbsp;&nbsp;32% |

---

First quarter 2026 Net Sales were $1.4 billion, an increase of 1% compared to the prior-year quarter. Reported Net Sales were primarily driven by a 2% increase in price and a 3% increase in currency, partially offset by a 4% decrease in volumes. The overall increase in price was driven by automotive Freon™ pricing for TSS in North America, partially offset by TT and APM. The decrease in volume was primarily driven by constraints in production due to an operational outage in

<sup>1</sup> Certain prior period amounts have been revised to correct for certain immaterial errors as further described in our Annual Report on Form 10-K for the year ended December 31, 2025.

<sup>2</sup> Non-GAAP measures, including Adjusted Net Income, Adjusted EPS and Adjusted EBITDA referred to throughout, principally exclude the impact of recent litigation settlements for legacy environmental matters and associated fees, in addition to other unallocated items – please refer to the attached "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)".

<sup>3</sup>Adjusted EBITDA excludes net income attributable to noncontrolling interests, net interest expense, depreciation and amortization, and all remaining provision for income taxes from Adjusted Net Income. See the corresponding reconciliation referenced in footnote #2.

<sup>4</sup>On a diluted earnings per share basis.

------

**EXHIBIT 99.1**

![img15408389_0.jpg](img15408389_0.jpg)

APM and weaker cyclical end markets impacting both TT and APM, partially offset by continued strength in TSS volume tied to increased Opteon™ Refrigerants adoption and Freon™ sales.

First quarter 2026 Net Loss attributable to Chemours was $29 million, or $0.19 per diluted share, compared to Net Loss attributable to Chemours of $5 million, or $0.03 per diluted share in the prior-year quarter. The larger first quarter Net Loss attributable to Chemours was driven by increased financing costs associated with a recent debt offering and higher Selling, General and Administrative costs. Adjusted EBITDA for the first quarter of 2026 was $169 million, compared to $166 million in the prior-year quarter with the referenced higher pricing, currency and other income more than offsetting overall higher costs paired with lower sales volumes in APM and TT.

**Thermal & Specialized Solutions**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Q1 2026** | &nbsp;&nbsp;**Q1 2025** | &nbsp;&nbsp;**Y-o-Y % ∆** | &nbsp;&nbsp;**Q4 2025** | &nbsp;&nbsp;**Q-o-Q % ∆** |
| &nbsp;&nbsp;Net Sales *(millions)* | &nbsp;&nbsp;$568 | &nbsp;&nbsp;$466 | &nbsp;&nbsp;22% | &nbsp;&nbsp;$444 | &nbsp;&nbsp;28% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Opteon™ Refrigerants* | &nbsp;&nbsp;&nbsp;*$313* | &nbsp;&nbsp;&nbsp;*$279* | &nbsp;&nbsp;&nbsp;*12%* | &nbsp;&nbsp;&nbsp;*$243* | &nbsp;&nbsp;&nbsp;*29%* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Freon™ Refrigerants* | &nbsp;&nbsp;&nbsp;*$162* | &nbsp;&nbsp;&nbsp;*$97* | &nbsp;&nbsp;&nbsp;*67%* | &nbsp;&nbsp;&nbsp;*$113* | &nbsp;&nbsp;&nbsp;*43%* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Foam, Propellants & Other (FP&O)* | &nbsp;&nbsp;&nbsp;*$93* | &nbsp;&nbsp;&nbsp;*$90* | &nbsp;&nbsp;&nbsp;*3%* | &nbsp;&nbsp;&nbsp;*$87* | &nbsp;&nbsp;&nbsp;*7%* |
| &nbsp;&nbsp;Adjusted EBITDA *(millions)* | &nbsp;&nbsp;$190 | &nbsp;&nbsp;$141 | &nbsp;&nbsp;35% | &nbsp;&nbsp;$128 | &nbsp;&nbsp;48% |
| &nbsp;&nbsp;Adjusted EBITDA Margin | &nbsp;&nbsp;33% | &nbsp;&nbsp;30% | &nbsp;&nbsp;3 ppts | &nbsp;&nbsp;29% | &nbsp;&nbsp;4 ppts |

---

For the first quarter of 2026, TSS segment results reflected both record sales, inclusive of a 12% year-over-year growth in Opteon™ Refrigerants, and Adjusted EBITDA.

TSS segment first quarter 2026 Net Sales were $568 million, an increase of 22% versus the prior-year quarter, driven by an 11% increase in price and a 9% increase in volume, with a 2% currency tailwind. Increased pricing was primarily driven by automotive Freon™ Refrigerant sales in North America. Volume growth was driven by the continued transition to Opteon<sup>™</sup>Refrigerants as well as automotive Freon™ Refrigerant sales in North America.

Adjusted EBITDA for the quarter increased 35% to $190 million, while Adjusted EBITDA Margin increased three points to 33%. The increase in Adjusted EBITDA was driven by higher pricing associated with the referenced automotive Freon™ sales and a transition to a more favorable product mix in Opteon™ Refrigerant blends, partially offset by higher input costs associated with R32, a key component of our stationary Opteon™ Refrigerant blends, in the quarter.

Sequentially, Net Sales increased 28%, driven by a 22% seasonal volume increase supported by a 6% pricing increase. Volumes followed seasonal patterns, increasing across all refrigerants.

------

**EXHIBIT 99.1**

![img15408389_0.jpg](img15408389_0.jpg)

**Titanium Technologies**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Q1 2026** | &nbsp;&nbsp;**Q1 2025** | &nbsp;&nbsp;**Y-o-Y % ∆** | &nbsp;&nbsp;**Q4 2025** | &nbsp;&nbsp;**Q-o-Q % ∆** |
| &nbsp;&nbsp;Net Sales *(millions)* | &nbsp;&nbsp;$559 | &nbsp;&nbsp;$597 | &nbsp;&nbsp;(6%) | &nbsp;&nbsp;$561 | &nbsp;&nbsp;(0%) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*TiO2 Pigment* | &nbsp;&nbsp;$541 | &nbsp;&nbsp;$575 | &nbsp;&nbsp;(6%) | &nbsp;&nbsp;$534 | &nbsp;&nbsp;1% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Minerals* | &nbsp;&nbsp;$18 | &nbsp;&nbsp;$22 | &nbsp;&nbsp;(18%) | &nbsp;&nbsp;$27 | &nbsp;&nbsp;(33%) |
| &nbsp;&nbsp;Adjusted EBITDA *(millions)* | &nbsp;&nbsp;$18 | &nbsp;&nbsp;$50 | &nbsp;&nbsp;(64%) | &nbsp;&nbsp;$23 | &nbsp;&nbsp;(22%) |
| &nbsp;&nbsp;Adjusted EBITDA Margin | &nbsp;&nbsp;3% | &nbsp;&nbsp;8% | &nbsp;&nbsp;(5) ppts | &nbsp;&nbsp;4% | &nbsp;&nbsp;(1) ppts |

---

TT segment first quarter 2026 Net Sales were $559 million, a 6% decrease compared to the prior-year quarter. This decrease was the result of a 7% decline in volumes globally, with favorable currency of 3% more than offsetting lower pricing of 2%. The decrease in volumes was driven by lower TiO2 sales concentrated in North America and certain non-western markets, which also negatively impacted product mix.

TT segment first quarter 2026 Adjusted EBITDA decreased 64% to $18 million compared to the prior-year quarter, while Adjusted EBITDA Margin decreased five percentage points to 3%. The decline in Adjusted EBITDA was primarily driven by the decline in sales as well as an unfavorable ore mix with Q1 production paired with decisions to adjust TT's mining footprint.

Sequentially, TT segment first quarter 2026 Net Sales were approximately flat, with a 3% increase in price, reflective of pricing actions announced in the fourth quarter of 2025, offset by a 3% decrease in volume.

**Advanced Performance Materials**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Q1 2026** | &nbsp;&nbsp;**Q1 2025** | &nbsp;&nbsp;**Y-o-Y % ∆** | &nbsp;&nbsp;**Q4 2025** | &nbsp;&nbsp;**Q-o-Q % ∆** |
| &nbsp;&nbsp;Net Sales *(millions)* | &nbsp;&nbsp;$243 | &nbsp;&nbsp;$294 | &nbsp;&nbsp;(17%) | &nbsp;&nbsp;$312 | &nbsp;&nbsp;(22%) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Advanced Materials* | &nbsp;&nbsp;&nbsp;*$143* | &nbsp;&nbsp;&nbsp;*$178* | &nbsp;&nbsp;&nbsp;*(20%)* | &nbsp;&nbsp;&nbsp;*$172* | &nbsp;&nbsp;&nbsp;*(17%)* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Performance Solutions* | &nbsp;&nbsp;&nbsp;*$100* | &nbsp;&nbsp;&nbsp;*$116* | &nbsp;&nbsp;&nbsp;*(14%)* | &nbsp;&nbsp;&nbsp;*$141* | &nbsp;&nbsp;&nbsp;*(29%)* |
| &nbsp;&nbsp;Adjusted EBITDA *(millions)* | &nbsp;&nbsp;$5 | &nbsp;&nbsp;$32 | &nbsp;&nbsp;(84%) | &nbsp;&nbsp;$12 | &nbsp;&nbsp;(58%) |
| &nbsp;&nbsp;Adjusted EBITDA Margin | &nbsp;&nbsp;2% | &nbsp;&nbsp;11% | &nbsp;&nbsp;(9) ppts | &nbsp;&nbsp;4% | &nbsp;&nbsp;(2) ppts |

---

APM segment first quarter 2026 Net Sales were $243 million, a 17% decrease compared to the prior-year quarter. This decrease was primarily driven by a 19% decrease in volume with favorable currency of 3% further offsetting a 1% decrease in price. The volume decline was primarily driven by sales constraints due to the Washington Works plant outage in Q1 and recent closure of APM's Advanced Materials SPS Capstone™ line, completed in the third quarter of 2025.

APM segment first quarter 2026 Adjusted EBITDA decreased 84% to $5 million compared to the prior-year quarter, while Adjusted EBITDA Margin decreased nine percentage points to 2%. The decrease in Adjusted EBITDA was primarily driven by the referenced lower sales volumes and related additional costs from the outage which combined for approximately $25 million for the quarter.

Sequentially, APM segment first quarter 2026 Net Sales were down approximately 22%, driven by a 22% decrease in volumes, related to decreased volumes across both Performance Solutions and Advanced Materials. The decline in volumes was due to the referenced first quarter Washington Works outage as well as contractual sales timing.

------

**EXHIBIT 99.1**

![img15408389_0.jpg](img15408389_0.jpg)

**Other Non-Reportable Segment**

The Performance Chemicals and Intermediates business in the Company's Other Non-Reportable Segment had Net Sales and Adjusted EBITDA for the first quarter 2026 of $11 million and $3 million, respectively.

**Corporate Expenses**

Corporate Expenses were $47 million in the first quarter of 2026, a decrease of approximately $10 million compared to the prior-year quarter. This was primarily due to lower costs associated with legacy litigation activities.

**Liquidity and Capital Allocation**

As of March 31, 2026, consolidated gross debt was $4.2 billion<sup>5</sup>. Debt, net of $563 million in unrestricted cash and cash equivalents, was $3.6 billion, resulting in a net leverage ratio of approximately 4.9x on a trailing twelve-month Adjusted EBITDA basis. Total liquidity was $1.5 billion, comprised of $563 million in unrestricted<sup>6</sup>cash and cash equivalents and $953 million of revolving credit facility capacity, net of outstanding letters of credit.

In April 2026, the Company completed the sale of nine of the ten parcels of land at the Company's Kuan Yin site which are classified as held-for-sale and received net cash proceeds of approximately $287 million. The sale of the tenth parcel of land is expected to be completed by the end of 2026 for a remaining gross purchase price of approximately $55 million. Using part of the initial cash proceeds received, as well as cash on hand, in April 2026, the Company paid down €140 million of the outstanding tranche B-3 Euro Term loans due August 2028. The Company expects further debt repayments in 2026.

Operating cash usage for the first quarter of 2026 was $44 million, compared to a usage of $112 million in the prior-year quarter highlighting improvements in net working capital performance.

Capital expenditures for the first quarter of 2026 amounted to $49 million, a decrease in spend compared to $84 million in the prior-year quarter, driven by lower capital expenditures in TSS.

Free Cash Flows for the first quarter of 2026 reflected a usage of $93 million, compared to a usage of $196 million in the first quarter of 2025.

<sup>5</sup>This amount does not reflect the €140 million used to reduce outstanding debt, which occurred in April of 2026.

<sup>6</sup>Restricted cash approximated $53 million of the end of the first quarter of 2026, reflecting primarily escrow payments Chemours has made related to the MOU agreement with DuPont, Corteva and EID as further described in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

------

**EXHIBIT 99.1**

![img15408389_0.jpg](img15408389_0.jpg)

**Second Quarter 2026 Outlook**

In the second quarter, the Company anticipates consolidated Net Sales to increase in the range of 15% to 20% sequentially, driven by favorable seasonal trends, with consolidated Adjusted EBITDA expected to range between $220 million and $250 million. Corporate Expenses are expected to approximate $45 million to $50 million. The Company also anticipates capital expenditures to approximate $50 million, with Free Cash Flows of at least $100 million.

TSS projects Net Sales will sequentially increase in the low-to-mid teens percentage range, driven by seasonality in connection with the 2026 cooling season in the northern hemisphere with strength in both Freon™ and Opteon™ Refrigerants. Adjusted EBITDA is expected to be between $210 million and $225 million.

TT expects an overall sequential Net Sales increase in the mid-to-high teens percentage range, driven by seasonal volume strength and a favorable mix for TiO2 pigment, supported by recent pricing actions, paired with increased minerals sales. Adjusted EBITDA is expected to range between $40 million and $50 million.

APM expects a sequential Net Sales increase in the low-to-high thirties percentage range, driven by a return to normal operating levels at the Washington Works facility while reflecting some limited residual impacts from the outage. Adjusted EBITDA for APM is expected to be between $12 million and $18 million.

**Full Year 2026 Outlook**

The Company continues to expect 2026 Net Sales to grow in the range of 3% to 5% over 2025, with Adjusted EBITDA between $800 million and $900 million. This outlook is supported by higher TSS and APM Performance Solutions demand, anticipated TT pricing momentum, and ongoing cost improvements in each business. Capital expenditures are anticipated to be between $275 million and $325 million, with overall Free Cash Flow Conversion above 20%, due to increased earnings and improvements in working capital throughout the year. This revised estimate now reflects the approximate $30 million estimated full year income tax cash outflow related to the expected proceeds to be distributed on the sale of land at the former Kuan Yin TiO2 site. As an update to previous expectations, the Company anticipates that these cash flow dynamics will produce a net leverage ratio of less than 3.8x by the end of 2026.

------

**EXHIBIT 99.1**

![img15408389_0.jpg](img15408389_0.jpg)

**Conference Call**

As previously announced, Chemours will hold a conference call and webcast on May 6, 2026, at 8:00 AM Eastern Time. The webcast and materials can be accessed by visiting the *Events & Presentations* page of Chemours' investor website, <u>investors.chemours.com</u>. A webcast replay of the conference call will be available on Chemours' investor website.

**About The Chemours Company**

The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit <u>chemours.com</u> or follow us on <u>LinkedIn</u>.

**Non-GAAP Financial Measures**

We prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). Within this press release, we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Free Cash Flows, Free Cash Flows Conversion, Total Debt Principal, Net and Net Leverage Ratio which are non-GAAP financial measures. The Company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Management uses Adjusted Net Income, Adjusted EPS and Adjusted EBITDA, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes in our underlying business from period to period. Additionally, Free Cash Flows, Free Cash Flows Conversion, Total Debt Principal, Net and Net Leverage Ratio are utilized as liquidity measures to assess the cash generation of our businesses and on-going liquidity position.

Accordingly, the Company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this press release, should be read in conjunction with the Company's financial statements and footnotes contained in the documents that the Company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the Company in this press release may be different from the methods used by other companies. The Company does not provide a reconciliation of certain forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)" and materials posted to the Company's website at investors.chemours.com.

------

**EXHIBIT 99.1**

![img15408389_0.jpg](img15408389_0.jpg)

**Forward-Looking Statements**

This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, guidance on Company and segment performance for the second quarter of 2026, the full year 2026 and the Company's corporate strategy. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, our ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the United States or other jurisdictions that affect demand for or adoption of our products, changes in regulations in the United States or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, global conflicts, changes in laws and regulations in the United States or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, and the Annual Report on Form 10-K for the year ended December 31, 2025. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

------

**EXHIBIT 99.1**

![img15408389_0.jpg](img15408389_0.jpg)

![img15408389_1.jpg](img15408389_1.jpg)

**CONTACTS:**

**INVESTORS**<br>*Brandon Ontjes*<br>*Vice President, Head of Strategy & Investor Relations*<br>*+1.302.773.3309*

*<u>investor@chemours.com</u>*<br>

**NEWS MEDIA**<br>*Cassie Olszewski*<br>*Media Relations & Reputation Leader*<br>*+1.302.219.7140*<br>*<u>media@chemours.com</u>*

------

**The Chemours Company**

**Consolidated Statements of Operations (Unaudited)**<sup>1</sup>

*(Dollars in millions, except per share amounts)*

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Net sales | $1381 | $1368 |
| Cost of goods sold | 1169 | 1132 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 212 | 236 |
| Selling, general, and administrative expense | 147 | 123 |
| Research and development expense | 26 | 27 |
| Restructuring, asset-related, and other charges | 13 | 33 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other operating expenses | 186 | 183 |
| Equity in earnings of affiliates | 8 | 8 |
| Interest expense, net | (69) | (66) |
| Loss on extinguishment of debt | (9) |  |
| Other income, net | 22 | 5 |
| **Loss before income taxes** | (22) |  |
| **Provision for income taxes** | 7 | 5 |
| **Net loss** | (29) | (5) |
| **Net loss attributable to Chemours** | $(29) | $(5) |
| **Per share data** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic (loss) earnings per share of common stock | $(0.19) | $(0.03) |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted (loss) earnings per share of common stock | (0.19) | (0.03) |

---

------

**The Chemours Company**

**Consolidated Balance Sheets (Unaudited)**<sup>1</sup>

*(Dollars in millions, except per share amounts)*

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | **December 31, 2025** |
| **Assets** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $563 | $670 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted cash and restricted cash equivalents |  | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts and notes receivable, net | 759 | 679 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories | 1536 | 1569 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other | 69 | 80 |
| &nbsp;&nbsp;&nbsp;&nbsp;Assets held for sale | 1 | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 2928 | 3001 |
| Property, plant, and equipment | 9925 | 9920 |
| Less: Accumulated depreciation | (6885) | (6842) |
| &nbsp;&nbsp;&nbsp;&nbsp;Property, plant, and equipment, net | 3040 | 3078 |
| Operating lease right-of-use assets | 274 | 271 |
| Goodwill | 46 | 46 |
| Other intangible assets, net | 2 | 2 |
| Investments in affiliates | 166 | 160 |
| Assets held for sale, non-current | 21 | 21 |
| Restricted cash and restricted cash equivalents | 52 | 52 |
| Other assets | 738 | 751 |
| **Total assets** | $7267 | $7382 |
| **Liabilities** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $891 | $954 |
| &nbsp;&nbsp;&nbsp;&nbsp;Compensation and other employee-related cost | 122 | 96 |
| &nbsp;&nbsp;&nbsp;&nbsp;Short-term and current maturities of long-term debt | 37 | 42 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current environmental remediation | 97 | 88 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other accrued liabilities | 462 | 506 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 1609 | 1686 |
| Long-term debt, net | 4100 | 4099 |
| Operating lease liabilities | 192 | 191 |
| Long-term environmental remediation | 520 | 530 |
| Deferred income taxes | 40 | 37 |
| Other liabilities | 590 | 588 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 7051 | 7131 |
| Commitments and contingent liabilities |  |  |
| **Equity** |  |  |
| Common stock (par value $0.01 per share; 810,000,000 shares authorized; 199,180,562 shares issued and 150,355,228 shares outstanding at March 31, 2026; 198,720,786 shares issued and 149,893,993 shares outstanding at December 31, 2025) | 2 | 2 |
| Treasury stock, at cost (48,825,334 shares at March 31, 2026 and 48,826,793 at December 31, 2025) | (1802) | (1802) |
| Additional paid-in capital | 1081 | 1074 |
| Retained earnings | 1178 | 1220 |
| Accumulated other comprehensive loss | (244) | (244) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Chemours stockholders' equity | 215 | 250 |
| Non-controlling interests | 1 | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total equity | 216 | 251 |
| **Total liabilities and equity** | $7267 | $7382 |

---

------

**The Chemours Company**

**Consolidated Statements of Cash Flows (Unaudited)**<sup>1</sup>

*(Dollars in millions)*

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| **Cash flows from operating activities** |  |  |
| Net loss | $(29) | $(5) |
| Adjustments to reconcile net income to cash used for operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 79 | 88 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss (gain) on sales of assets and businesses |  | (1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity in earnings of affiliates, net | (6) | (7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on extinguishment of debt | 9 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt issuance costs and issue discounts | 3 | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred tax benefit | (11) | (14) |
| &nbsp;&nbsp;&nbsp;&nbsp;Asset-related charges | 1 | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | 7 | 5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net periodic pension cost (income) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Defined benefit plan contributions | (1) | (4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other operating charges and credits, net | (14) | 37 |
| &nbsp;&nbsp;&nbsp;&nbsp;Decrease (increase) in operating assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts and notes receivable, net | (77) | (111) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories and other current operating assets | 32 | (51) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other non-current operating assets | 17 | 48 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Decrease) increase in operating liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (58) | (105) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current operating liabilities | 12 | (5) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other non-current operating liabilities | (8) | 9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash used for operating activities | (44) | (112) |
| **Cash flows from investing activities** |  |  |
| Purchases of property, plant, and equipment | (49) | (84) |
| Proceeds from life insurance policies | 1 |  |
| Proceeds from sales of assets and businesses | 7 |  |
| Foreign exchange contract settlements, net | (3) | (2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash used for investing activities | (44) | (86) |
| **Cash flows from financing activities** |  |  |
| Proceeds from issuance of debt | 700 |  |
| Debt repayments | (689) | (8) |
| Payments on finance leases | (3) | (3) |
| Payments of debt issuance cost | (10) |  |
| Proceeds from supplier financing program | 16 | 27 |
| Payments to supplier financing program | (14) | (35) |
| Proceeds from exercised stock options, net | 2 |  |
| Payments related to tax withholdings on vested stock awards | (2) | (1) |
| Payments of dividends to the Company's common shareholders | (13) | (37) |
| Debt extinguishment payments | (6) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash used for financing activities | (19) | (57) |
| Effect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash equivalents | (2) | 6 |
| **Decrease in cash, cash equivalents, restricted cash and restricted cash equivalents** | (109) | (249) |
| **Cash, cash equivalents, restricted cash and restricted cash equivalents at January 1,** | 724 | 763 |
| **Cash, cash equivalents, restricted cash and restricted cash equivalents at March 31,** | $615 | $514 |
| **Supplemental cash flows information** |  |  |
| Non-cash investing and financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of property, plant, and equipment included in accounts payable | $27 | $26 |

---

------

**The Chemours Company**

**Segment Financial and Operating Data (Unaudited)**

*(Dollars in millions)*

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Segment Net Sales**<sup>1</sup> |  |  |  | **Three Months** |  |
|  |  |  |  | **Ended** | **Sequential** |
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Increase /** | **December 31,** | **Increase /** |
|  | **2026** | **2025** | **(Decrease)** | **2025** | **(Decrease)** |
| Thermal & Specialized Solutions | $568 | $466 | $102 | $444 | $124 |
| Titanium Technologies | 559 | 597 | (38) | 561 | (2) |
| Advanced Performance Materials | 243 | 294 | (51) | 312 | (69) |
| Other Non-Reportable Segment | 11 | 11 | 0 | 12 | (1) |
| **Total Net Sales** | $1381 | $1368 | $13 | $1329 | $52 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Segment Adjusted EBITDA**<sup>1</sup> | **Segment Adjusted EBITDA**<sup>1</sup> |  |  | **Three Months** |  |
|  |  |  |  | **Ended** | **Sequential** |
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Increase /** | **December 31,** | **Increase /** |
|  | **2026** | **2025** | **(Decrease)** | **2025** | **(Decrease)** |
| Thermal & Specialized Solutions | $190 | $141 | $49 | $128 | $62 |
| Titanium Technologies | $18 | $50 | $(32) | $23 | $(5) |
| Advanced Performance Materials | $5 | $32 | $(27) | $12 | $(7) |
| Other Non-Reportable Segment | $3 | $1 | $2 | $1 | $2 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Quarterly Change in Net Sales from the three months ended March 31, 2025** | **Quarterly Change in Net Sales from the three months ended March 31, 2025** | **Quarterly Change in Net Sales from the three months ended March 31, 2025** | **Quarterly Change in Net Sales from the three months ended March 31, 2025** | **Quarterly Change in Net Sales from the three months ended March 31, 2025** | **Quarterly Change in Net Sales from the three months ended March 31, 2025** | **Quarterly Change in Net Sales from the three months ended March 31, 2025** |
|  | **March 31, 2026** | **Percentage Change vs.** | **Percentage Change Due To** | **Percentage Change Due To** | **Percentage Change Due To** | **Percentage Change Due To** |
|  | **Net Sales** | **March 31, 2025** | **Price** | **Volume** | **Currency** | **Portfolio** |
| Total Company | $1381 | 1% | 2% | (4)% | 3% | —% |
| Thermal & Specialized Solutions | $568 | 22% | 11% | 9% | 2% | —% |
| Titanium Technologies | 559 | (6)% | (2)% | (7)% | 3% | —% |
| Advanced Performance Materials | 243 | (17)% | (1)% | (19)% | 3% | —% |
| Other Non-Reportable Segment | 11 | —% | (2)% | 2% | —% | —% |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Quarterly Change in Net Sales from the three months ended December 31, 2025** | **Quarterly Change in Net Sales from the three months ended December 31, 2025** | **Quarterly Change in Net Sales from the three months ended December 31, 2025** | **Quarterly Change in Net Sales from the three months ended December 31, 2025** | **Quarterly Change in Net Sales from the three months ended December 31, 2025** | **Quarterly Change in Net Sales from the three months ended December 31, 2025** | **Quarterly Change in Net Sales from the three months ended December 31, 2025** |
|  | **March 31, 2026** | **Percentage Change vs.** | **Percentage Change Due To** | **Percentage Change Due To** | **Percentage Change Due To** | **Percentage Change Due To** |
|  | **Net Sales** | **December 31, 2025** | **Price** | **Volume** | **Currency** | **Portfolio** |
| Total Company | $1381 | 4% | 3% | 1% | —% | —% |
| Thermal & Specialized Solutions | $568 | 28% | 6% | 22% | —% | —% |
| Titanium Technologies | 559 | —% | 3% | (3)% | —% | —% |
| Advanced Performance Materials | 243 | (22)% | —% | (22)% | —% | —% |
| Other Non-Reportable Segment | 11 | (2)% | 5% | (7)% | —% | —% |

---

------

**The Chemours Company**

**Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)**

*(Dollars in millions)*

**<u>GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation</u>**

 **<u>GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation</u>**<sup>1</sup>

Adjusted earnings before interest, taxes, depreciation, and amortization ("Adjusted EBITDA") is defined as income (loss) before income taxes, excluding the following items: interest expense, depreciation, and amortization; non-operating pension and other post-retirement employee benefit costs, which represents the components of net periodic pension costs excluding the service cost component; exchange (gains) losses included in other income (expense), net; restructuring, asset-related, and other charges; (gains) losses on sales of businesses or assets; and, other items not considered indicative of the Company's ongoing operational performance and expected to occur infrequently, including certain litigation related and environmental charges and Qualified Spend reimbursable by DuPont and/or Corteva as part of the Company's cost-sharing agreement under the terms of the MOU that were previously excluded from Adjusted EBITDA. Adjusted Net Income is defined as net income (loss) attributable to Chemours, adjusted for items excluded from Adjusted EBITDA, except interest expense, depreciation, amortization, and certain provision for (benefit from) income tax amounts. Net Leverage Ratio is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Twelve Months Ended** | **Twelve Months Ended** |
|  | **March 31,** | **March 31,** | **December 31,** | **March 31,** | **March 31,** |
|  | **2026** | **2025** | **2025** | **2026** | **2025** |
| **(Loss) income before income taxes** | $(22) | $— | $(67) | (299) | 38 |
| **Net (loss) income attributable to Chemours** | $(29) | $(5) | $(47) | (409) | 12 |
| Non-operating pension and other post-retirement employee benefit (income) cost | (2) | (2) | (3) | (11) | (5) |
| Exchange (gains) losses, net | (1) | 3 | 4 | 8 | 13 |
| Restructuring, asset-related, and other charges (1) | 13 | 32 | 4 | 39 | 85 |
| Goodwill impairment charge (2) |  |  |  |  | 56 |
| Loss (gain) on extinguishment of debt (3) | 9 |  | 5 | 14 | 1 |
| Gain on sales of assets and businesses, net (4) |  | (1) |  | (7) | (1) |
| Transaction costs (5) | 2 |  | 4 | 8 | 2 |
| Qualified spend recovery (6) | (5) | (9) | (7) | (38) | (28) |
| Litigation-related charges (7) | 20 |  | 19 | 340 | 2 |
| Environmental charges (8) | 7 |  | 20 | 100 | 15 |
| Adjustments made to income taxes (9) | 1 | 1 | 19 | 181 | 9 |
| (Benefit from) provision for income taxes relating to reconciling items (10) | (7) |  | (11) | (92) | (9) |
| **Adjusted Net Income** | 8 | 19 | 7 | 133 | 152 |
| Net income attributable to non-controlling interests |  |  | (1) |  |  |
| Interest expense, net | 69 | 66 | 68 | 272 | 267 |
| Depreciation and amortization (11) | 79 | 77 | 81 | 319 | 299 |
| All remaining provision for income taxes (10) | 13 | 4 | (27) | 22 | 25 |
| **Adjusted EBITDA** | $169 | $166 | $128 | $746 | $743 |
| Total debt principal |  |  |  | 4183 | 4147 |
| Less: Cash and cash equivalents |  |  |  | (563) | (464) |
| **Total debt principal, net** |  |  |  | $3620 | $3683 |
| **Net Leverage Ratio (calculated using GAAP earnings) (12)** |  |  |  | (12.1)x | 96.9x |
| **Net Leverage Ratio (calculated using Non-GAAP earnings) (12)** |  |  |  | 4.9x | 5x |

---

------

**<u>GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation</u>**

 **<u>GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation (Continued)</u>**<sup>1</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)For the twelve months ended March 31, 2026, restructuring, asset-related and other charges primarily includes employee separation charges related to the 2026 Restructuring Program as well as charges related to our decision to exit our SPS Capstone<sup>TM</sup> business. For the twelve months ended March 31, 2025, restructuring, asset-related and other charges primarily include charges related to our decision to exit our SPS Capstone<sup>TM</sup> business and the 2024 Restructuring Program. See "Note 4 –Restructuring, Asset-Related and Other Charges" to the *Interim Consolidated Financial Statements* in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 for further details.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)For the twelve months ended March 31, 2025, this represents a non-cash goodwill impairment charge in the Advanced Performance Materials unit, which is discussed further in "Note 15 – Goodwill and Other Intangibles, Net" to the *Consolidated Financial Statements* in our Annual Report on Form 10-K for the year ended December 31, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)For the twelve months ended March 31, 2026, loss on extinguishments of debt reflects costs associated with early redemption of the 2027 senior unsecured notes and partial early redemption of our 2028 senior unsecured notes during the first quarter of 2026. See "Note 15 - Debt" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 for further details.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)For the twelve months ended March 31, 2026, gain on sales of assets and businesses, net includes a gain on sale of $7 million related to certain parcels of land at the Company's manufacturing site in Kuan Yin, Taiwan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)For the twelve months ended March 31, 2025, transaction costs include $4 million of costs associated with the Senior Secured Credit Facilities. See "Note 15 - Debt" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 for further details.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)Qualified spend recovery represents costs and expenses that were previously excluded from Adjusted EBITDA, reimbursable by DuPont and/or Corteva as part of our cost-sharing agreement under the terms of the MOU which is discussed in further detail in "Note 17 – Commitments and Contingent Liabilities" to the *Interim Consolidated Financial Statements* in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7)Litigation-related charges pertain to litigation settlements, PFOA drinking water treatment accruals, and other related legal fees. For the twelve months ended March 31, 2026, litigation-related charges primarily includes $266 million related to the Company's portion of Chemours, DuPont, Corteva, EID and the State of New Jersey's settlement agreement reached in August 2025, $12 million in third-party legal fees directly related to the New Jersey Settlement agreement, $14 million related to the Company's portion of Chemours, DuPont, Corteva, EID's settlement agreement to resolve the Hoosick Falls class action lawsuit, $15 million related to alleged violations and discharge exceedances and $18 million related to reserves for asbestos and production liability matters. For the twelve months ended March 31, 2025, litigation-related charges include a $29 million accrual associated with the Ohio MDL and $27 million of benefits from insurance recoveries. See "Note 17 – Commitments and Contingent Liabilities" to the *Interim Consolidated Financial Statements* in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 for further details.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(8)Environmental charges pertain to management's assessment of estimated liabilities associated with certain remediation expenses at various sites. For the twelve months ended March 31, 2026, environmental charges primarily include changes to remediation reserves at the four sites covered by the New Jersey settlement agreement. See "Note 17 – Commitments and Contingent Liabilities" to the *Interim Consolidated Financial Statements* in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 for further details.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(9)Includes the removal of certain discrete income tax impacts within our provision for income taxes, such as shortfalls and windfalls on our share-based payments, certain return-to-accrual adjustments, valuation allowance adjustments, unrealized gains and losses on foreign exchange rate changes, and other discrete income tax items.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(10)The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred for each of the reconciling items and represent both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(11)For the twelve months ended March 31, 2026 and March 31, 2025, accelerated depreciation charges of $12 million and $11 million, respectively, incurred as part of our decision to exit our SPS Capstone<sup>TM</sup> business are included within the "Restructuring, asset-related and other charges" caption above, and therefore are not included as separate adjustment within this caption.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(12)Net Leverage Ratio calculated using GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by income (loss) before income taxes. Net Leverage Ratio calculated using non-GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA.

------

**The Chemours Company**

**Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)**

*(Dollars in millions, except per share amounts)*

**<u>GAAP Earnings per Share to Adjusted Earnings per Share Reconciliation</u>**<sup>1</sup>

Adjusted earnings per share ("Adjusted EPS") is calculated by dividing Adjusted Net Income by the weighted-average number of common shares outstanding. Diluted Adjusted EPS accounts for the dilutive impact of stock-based compensation awards, which include unvested restricted shares. Diluted Adjusted EPS considers the impact of potentially-dilutive securities, except in periods in which there is a loss because the inclusion of the potentially-dilutive securities would have an anti-dilutive effect.

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** | **December 31,** |
|  | **2026** | **2025** | **2025** |
| Numerator: |  |  |  |
| &nbsp;&nbsp;Net (loss) income attributable to Chemours | $(29) | $(5) | $(47) |
| &nbsp;&nbsp;Adjusted Net Income | 8 | 19 | 7 |
| Denominator: |  |  |  |
| &nbsp;&nbsp;Weighted-average number of common shares outstanding - basic | 150767077 | 149918386 | 150464150 |
| &nbsp;&nbsp;Dilutive effect of the Company's employee compensation plans (1) | 819728 | 491194 | 398511 |
| &nbsp;&nbsp;Weighted-average number of common shares outstanding - diluted (1) | 151586805 | 150409579 | 150862661 |
| Basic (loss) earnings per share of common stock (2) | $(0.19) | $(0.03) | $(0.31) |
| Diluted (loss) earnings per share of common stock (1) (2) | (0.19) | (0.03) | (0.31) |
| Adjusted basic earnings per share of common stock (2) | 0.05 | 0.13 | 0.05 |
| Adjusted diluted earnings per share of common stock (1) (2) | 0.05 | 0.13 | 0.05 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under U.S. GAAP, as their inclusion would have an anti-dilutive effect. As such, with respect to the U.S. GAAP measure of diluted EPS, the impact of potentially dilutive securities is excluded from our calculation for the three months ended March 31, 2026, three months ended March 31, 2025 and the three months ended December 31, 2025. With respect to the non-GAAP measure of adjusted diluted EPS, the impact of potentially dilutive securities is included in our calculation for the three months ended March 31, 2026, three months ended March 31, 2025 and the three months ended December 31, 2025 as Adjusted Net Income was in a net income position.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Figures may not recalculate exactly due to rounding. Basic and diluted earnings (loss) per share are calculated based on unrounded numbers.

------

**The Chemours Company**

**Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)**

*(Dollars in millions, except per share amounts)*

**<u>GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash Flow Conversion Reconciliation</u>** 

<br> Free Cash Flows is defined as cash flows provided by (used for) operating activities, less purchases of property, plant and equipment as shown in the consolidated statements of cash flows. Free Cash Flow Conversion is calculated as the percentage of Free Cash Flows to Adjusted EBITDA.

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** | **December 31,** |
|  | **2026** | **2025** | **2025** |
| Cash flows (used for) provided by operating activities | $(44) | $(112) | $137 |
| Less: Purchases of property, plant, and equipment | (49) | (84) | (45) |
| **Free Cash Flows** | $(93) | $(196) | $92 |
| Adjusted EBITDA | 169 | 166 | 128 |
| **Free Cash Flow Conversion** | (55)% | (118)% | 72% |

---

**<u>2026 Estimated GAAP Cash Flow Provided by Operating Activities to Estimated Free Cash Flows and Estimated Free Cash Flow Conversion Reconciliation (1)</u>** 

<br> Free Cash Flows is defined as cash flows provided by (used for) operating activities, less purchases of property, plant and equipment as shown in the consolidated statements of cash flows. Free Cash Flow Conversion is calculated as the percentage of Free Cash Flows to Adjusted EBITDA.

---

| | | |
|:---|:---|:---|
|  | **Estimated** | **Estimated** |
|  | **Year Ended December 31, 2026** | **Year Ended December 31, 2026** |
|  | **Low** | **High** |
| Cash flows provided by (used for) operating activities | $445 | $565 |
| Less: Purchases of property, plant, and equipment | (275) | (325) |
| **Free Cash Flows** | $170 | $240 |
| Adjusted EBITDA | 800 | 900 |
| **Free Cash Flow Conversion** | 21% | 27% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Cash flows provided by operating activities is inclusive of the anticipated $30 million cash taxes associated with the sale of the Kuan Yin site.

**<u>2026 Estimated GAAP Net Income Attributable to Chemours to Estimated Adjusted Net Income and Estimated Adjusted EBITDA Reconciliation (1)</u>**

---

| | | |
|:---|:---|:---|
|  | **(Estimated)** | **(Estimated)** |
|  | **Year Ending December 31, 2026** | **Year Ending December 31, 2026** |
|  | **Low** | **High** |
| **Net income attributable to Chemours** | $165 | $225 |
| Restructuring, transaction, and other costs, net (2) | (35) | (45) |
| **Adjusted Net Income** | 130 | 180 |
| Interest expense, net | 275 | 285 |
| Depreciation and amortization | 315 | 325 |
| All remaining provision for income taxes | 80 | 110 |
| **Adjusted EBITDA** | $800 | $900 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Company's estimates reflect its current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. Actual results could differ materially from these estimates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Restructuring, transaction, and other costs, net includes the net benefit from income taxes relating to reconciling items and adjustments made to income taxes for the removal of certain discrete income tax impacts.

------